Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 25

recruiting
3 968
countries
28
conditions
2 103

441 trials match your criteria

Non-small cell lung cancer+2

Not recruiting

Study on the Safety of Continued Treatment with GME751 (Pembrolizumab Biosimilar) for Patients with Melanoma or Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen

Interstitial lung disease

Not recruiting

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Bi 1015550

Plasma cell myeloma

Not recruiting

Study on the Effects of Isatuximab with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Plasma cell myeloma

Not recruiting

Study of belantamab mafodotin with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Neoplasm

Not recruiting

Study of Vusolimogene Oderparepvec and Nivolumab for Patients with Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Obexelimab

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab

Small cell lung cancer metastatic

Not recruiting

Study of Lurbinectedin and Atezolizumab in Patients with Advanced Small Cell Lung Cancer Who Have Previously Received Platinum Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Neoplasm malignant+1

Not recruiting

Study of ACP-017 and Pembrolizumab for Patients with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acp-017

Hodgkin's disease

Not recruiting

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin

Endometrial cancer recurrent

Not recruiting

Study on Durvalumab, Olaparib, and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer in Spain

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.